港股医药板块再度走强，港股创新药ETF（159567）早盘涨超3%

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a strong rally, driven by increased demand for flu-related medications and the growth of innovative domestic drugs in international markets [1] Group 1: Market Performance - The Hong Kong pharmaceutical sector saw significant gains, with companies like InnoCare Pharma, Rongchang Bio, CSPC Pharmaceutical, and 3SBio all rising over 6% [1] - The Hong Kong Innovative Drug ETF (159567) increased by over 3% as of 9:51 AM, with a trading volume exceeding 600 million yuan [1] - As of November 25, the ETF has recorded a net inflow of 903 million yuan for the month [1] Group 2: Demand Trends - There is a notable increase in demand for flu medications on the Alibaba Health platform, with a more than 500% week-on-week growth in the number of buyers for antiviral flu drugs during the recent two weeks (November 10-23) [1] Group 3: Industry Outlook - Institutions believe that more domestic innovative drugs are achieving value upgrades through international expansion, with overseas licensing transaction amounts reaching new highs, providing new momentum for sector growth [1] - The long-term positive trend in the innovative drug industry is expected to continue, extending from performance realization to business development in international markets [1]